Cognition Therapeutics (CGTX) Net Cash Flow (2020 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Net Cash Flow of -$5.8 million for Q1 2026, up 32.7% year-over-year from -$4.4 million in Q1 2025, and down 103.92% quarter-over-quarter from -$2.8 million in Q4 2025.
Cognition Therapeutics (CGTX) Net Cash Flow (2020 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Net Cash Flow for 7 consecutive years, with -$5.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 32.7% year-over-year to -$5.8 million; the TTM figure through Mar 2026 stood at $14.8 million (up 181.07% YoY), while the FY2025 annual figure was $12.0 million, up 344.07% from the prior year.
- Net Cash Flow slipped to -$5.8 million in Q1 2026 per CGTX's latest filing, from -$2.8 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $28.3 million in Q3 2025 and bottomed at -$8.6 million in Q1 2025.
- Historically, Net Cash Flow has averaged -$1.4 million across 5 years, with a median of -$3.2 million in 2022.
- Annual changes were most pronounced in 2023 — Net Cash Flow plunged 601.43% — and 2025, when it soared 533.39%.
- Cognition Therapeutics' Net Cash Flow stood at -$5.1 million in 2022, then surged by 39.69% to -$3.0 million in 2023, then jumped by 198.39% to $3.0 million in 2024, then slumped by 194.46% to -$2.8 million in 2025, then plunged by 103.92% to -$5.8 million in 2026.
- Business Quant data shows CGTX's Net Cash Flow at -$5.8 million in Q1 2026, -$2.8 million in Q4 2025, and $28.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | 3.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.56 Mn |
| Jun 30, 2026 | 3.56 Mn |
| Mar 31, 2026 | -5.78 Mn |
| Mar 31, 2026 | -5.78 Mn |
| Dec 31, 2025 | -2.83 Mn |
| Dec 31, 2025 | -2.83 Mn |
| Sep 30, 2025 | 28.27 Mn |
| Sep 30, 2025 | 28.27 Mn |
| Jun 30, 2025 | -4.87 Mn |
| Jun 30, 2025 | -4.87 Mn |
| Mar 31, 2025 | -8.58 Mn |
| Mar 31, 2025 | -8.58 Mn |
| Dec 31, 2024 | 3.00 Mn |
| Dec 31, 2024 | 3.00 Mn |
| Sep 30, 2024 | -6.52 Mn |
| Sep 30, 2024 | -6.52 Mn |
| Jun 30, 2024 | -6.14 Mn |
| Jun 30, 2024 | -6.14 Mn |
| Mar 31, 2024 | 4.75 Mn |
| Mar 31, 2024 | 4.75 Mn |